Efficacy and safety of oral poliovirus vaccine and inactivated poliovirus vaccine.

Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.

Affordable inactivated poliovirus vaccine: strategies and progress.

Use of inactivated or oral poliovirus vaccine in India.

Use of inactivated or oral poliovirus vaccine in India.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Immune response of infants to inactivated poliovirus vaccine injected intradermally.

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.

Immune response to intradermally injected inactivated poliovirus vaccine.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

Early immunization of neonates with trivalent oral poliovirus vaccine.

Potency of field samples of oral poliovirus vaccine.

Modeling the dynamics of oral poliovirus vaccine cessation.

Use of oral poliovirus vaccine for unlicensed indications.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance.

Choice between inactivated and oral poliovirus vaccines in India.

$Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.$
Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.

Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine.

Suggest Documents

Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization.

Affordable inactivated poliovirus vaccine: strategies and progress.

Use of inactivated or oral poliovirus vaccine in India.

Use of inactivated or oral poliovirus vaccine in India.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs.

Immune response of infants to inactivated poliovirus vaccine injected intradermally.

Safety of diphtheria, tetanus, acellular pertussis and inactivated poliovirus (DTaP-IPV) vaccine.

Immune response to intradermally injected inactivated poliovirus vaccine.

Intradermal inactivated poliovirus vaccine: a preclinical dose-finding study.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.

Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial.

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy.

Early immunization of neonates with trivalent oral poliovirus vaccine.

Potency of field samples of oral poliovirus vaccine.

Modeling the dynamics of oral poliovirus vaccine cessation.

Use of oral poliovirus vaccine for unlicensed indications.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication.

Switch from oral to inactivated poliovirus vaccine in Yogyakarta Province, Indonesia: summary of coverage, immunity, and environmental surveillance.

Choice between inactivated and oral poliovirus vaccines in India.

Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.

Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame.

Cold-Adapted Viral Attenuation (CAVA): Highly Temperature Sensitive Polioviruses as Novel Vaccine Strains for a Next Generation Inactivated Poliovirus Vaccine.

Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine.

Efficacy and safety of oral poliovirus vaccine and inactivated poliovirus vaccine.

Recommend Documents

Follow Us